$CELG News The market puts a few feathers in its cap 1:58

New Post Public Reply Private Reply Replies (0) Message Board

Feb 26, 2014 at 12:28 PM

$CELG News

The market puts a few feathers in its cap 1:58 p.m. Jan. 23, 2014 - The Trading Deck
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Celgene's 2014 guidance falls below analyst views 12:19 p.m. Jan. 13, 2014 - MarketWatch.com
Clovis Oncology, seen as 'next ICPT,' jumps 5% 9:47 a.m. Jan. 13, 2014 - Victor Reklaitis
Intercept, Celgene on move amid J.P. Morgan event 9:20 a.m. Jan. 13, 2014 - Victor Reklaitis
Epizyme shares surge 65% after cancer therapy hits milestone 11:06 a.m. Jan. 7, 2014 - Russ Britt
Sirius soars; Twitter tumbles on downgrade 3:50 p.m. Jan. 6, 2014 - Wallace Witkowski
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Sorry, haters: Unloved stocks had a great year 7:41 a.m. Dec. 30, 2013 - Brett Arends
These S&P winners have room to grow in 2014 6:00 a.m. Dec. 23, 2013 - Jeff Reeves
Two growth stocks that look ready to fly 1:29 p.m. Dec. 12, 2013 - The Trading Deck
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
What the worst advisers are recommending 1:16 p.m. Nov. 21, 2013 - Mark Hulbert
Top performers’ top November bets 11:01 p.m. Nov. 3, 2013 - Mark Hulbert
Celgene raises earnings outlook as sales climb 7:27 a.m. Oct. 24, 2013 - MarketWatch.com
A bull market as typical as any other 11:23 a.m. Oct. 22, 2013 - The Trading Deck
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
Market uptrend bends, without cracking 11:55 a.m. Oct. 1, 2013 - Michael Ashbaugh
Market technicals bend, without cracking 11:38 a.m. Oct. 1, 2013 - Michael Ashbaugh
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck

Putting the biotech boom in perspective 12:54 p.m. Feb. 24, 2014 - Seeking Alpha
What To Buy: Celgene Corporation's Buy Recommendation Reiterated 9:00 a.m. Feb. 24, 2014 - TheStreet.com
Catalysts Drive These Stocks: Mara Goldstein 9:20 a.m. Feb. 21, 2014 - Seeking Alpha
Can CELG Clear Key Resistance? 9:00 a.m. Feb. 21, 2014 - RealMoney.com
Placenta Based Treatments Crowding Out Legacy Products In Wound Care 8:34 a.m. Feb. 21, 2014 - Seeking Alpha
Who Is Responsible For Biotech's Torrid Start to 2014? 4:03 p.m. Feb. 20, 2014 - TheStreet.com
REGN, BIIB And CELG, Pushing Drugs Industry Downward 12:04 p.m. Feb. 19, 2014 - TheStreet.com
Celgene Corporation (CELG): Today's Featured Health Care Winner 5:00 p.m. Feb. 18, 2014 - TheStreet.com
Celgene Plans Stock Split - Analyst Blog 5:34 p.m. Feb. 14, 2014 - Zacks.com
Big Pharma Will Find Good Hunting Among Early-Stage Biotechs: Dhesh Govender 11:56 a.m. Feb. 14, 2014 - Seeking Alpha
AbbVie Deserves More Respect 6:30 a.m. Feb. 14, 2014 - TheStreet.com
10-K: CELGENE CORP /DE/ 4:04 p.m. Feb. 13, 2014 - Edgar Online - (EDG = 10Q, 10K)
Market Wrap For February 13: Markets Close Higher; Nasdaq on a Six Day Winning Streak 3:50 p.m. Feb. 13, 2014 - benzinga.com
Regenerative Medicine Finally Gets Some Respect: Reni Benjamin 9:23 a.m. Feb. 13, 2014 - Seeking Alpha
IPO Preview: Concert Pharmaceuticals 1:00 a.m. Feb. 13, 2014 - Seeking Alpha
Jim Cramer's 6 Stocks in 60 Seconds: BUD S LNG VJET SGEN CROX 5:08 p.m. Feb. 12, 2014 - TheStreet.com
Short Sellers Shy Away From Biotechs 6:04 a.m. Feb. 12, 2014 - 247WallSt.com
Celgene Corporation Continues With Buy Recommendation 9:00 a.m. Feb. 11, 2014 - TheStreet.com
Health Canada Approves (Pr)POMALYST(TM) (Pomalidomide Capsules) Providing New Hope For Patients With Progressive Multiple Myeloma 6:30 a.m. Feb. 11, 2014 - CNW Group
You Can No Longer Ignore Biotech 4:32 p.m. Feb. 7, 2014 - GuruFocus.com

Celgene Corporation Board of Directors Recommends to Our Stockholders a Two-for-One Stock Split 7:30 a.m. Feb. 13, 2014 - BusinessWire - BZX
Celgene Corporation to Present at Investor Conferences in February and March 8:30 a.m. Feb. 11, 2014 - BusinessWire - BZX
Grant & Eisenhofer Represents Whistleblower Accusing Celgene Corp. of Off-Label Marketing of High-Risk Cancer Drugs Derived from Thalidomide 2:11 p.m. Feb. 6, 2014 - PR Newswire - PRF
Critical Alerts For Baidu.com, Endo Pharmaceuticals, Mattel, Celgene, and Tyson Foods Released By InvestorsObserver 9:31 a.m. Feb. 4, 2014 - PR Newswire - PRF
Celgene Reports Fourth Quarter and Full Year 2013 Operating and Financial Results 7:32 a.m. Jan. 30, 2014 - BusinessWire - BZX
Celgene Corporation to Announce Fourth Quarter and Full Year 2013 Results on January 30, 2014 8:30 a.m. Jan. 22, 2014 - BusinessWire - BZX
Celgene Corporation Announces 2014 Financial Outlook and Preliminary 2013 Results 11:29 a.m. Jan. 13, 2014 - BusinessWire - BZX
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
ABRAXANE(R) Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer 6:01 a.m. Jan. 7, 2014 - BusinessWire
Critical Alerts For Google, Celgene, Salesforce.com, Chesapeake Energy, and Endo Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Jan. 3, 2014 - PR Newswire
Celgene Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference 8:29 a.m. Jan. 2, 2014 - BusinessWire
Presentation of Clinical Study Data, Prestigious Accolades, and Acquisitions - Research Report on Celgene, UnitedHealth, AstraZeneca, Mylan, and Valeant 8:00 a.m. Dec. 25, 2013 - PR Newswire
Clinical Study Data Presentation, Product Launches, Technology Deployments, and Stock Price Movements - Research Report on Celgene, Mylan, Valeant, Health Management, and CareFusion 8:00 a.m. Dec. 17, 2013 - PR Newswire
Atara Biotherapeutics Secures $38.5 Million Series B Financing 7:00 a.m. Dec. 17, 2013 - BusinessWire
Agios Advances Cancer Metabolism Collaboration with Celgene 8:16 a.m. Dec. 11, 2013 - BusinessWire
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH 7:00 p.m. Dec. 10, 2013 - BusinessWire
Two Studies Highlight Retrospective Analyses of Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Patients Presented at ASH 8:30 a.m. Dec. 10, 2013 - BusinessWire
REVLIMID(R) (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response 7:30 p.m. Dec. 9, 2013 - BusinessWire
Stock Price Movements, Completed Acquisitions, and New Clinical Studies - Research Report on UnitedHealth Group, Mylan, St. Jude Medical, and Cigna 8:00 a.m. Dec. 9, 2013 - PR Newswire
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH 9:37 p.m. Dec. 7, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI-Powered Bank Set to Transform Bahrain's Financial Landscape

A Fresh Approach to Banking in Bahrain The stuff that's stirring the pot in Bahrain’s financial sector right now? This big ol' partnership between Mumtalakat, the Kingdom's sovereign wealth fund, and ARP Group. They're on a mission to launch an AI-native wholesale bank smack dab in Bahrain. But here’s the kicker – they’ve got the green light, in principle at...

Lazard Closes Deal with Campbell, Launches Lazard CL

Talk about pulling a rabbit out of the hat! Lazard has just solidified its position in the private capital advisory game with the closure of its acquisition of Campbell Lutyens. They’re now rolling out Lazard CL, merging muscle across different strategies and diversifying those good ol’ revenue streams. It’s a peppy move from Lazard—not just for the cold hard...

ElektraFi Challenges Starlink: Fixed Wireless Gains Edge

Revolution or Just Better Options? In the wild west of internet connectivity, where every home is a frontier, ElektraFi is throwing down the gauntlet at the feet of behemoths like Starlink. They're talking big about their fixed wireless network, and in places stretching from Colorado's ski slopes to the dustier reaches of Texas, that talk might just hold some weight. Why...

Hexagon Seals Waygate Deal, Targets Inspection Leadership

Hexagon's Bold Move into Non-Destructive Testing Hexagon's latest play is turning heads in the measurement technology market. They've just wrapped up a strategic acquisition, snagging none other than Waygate Technologies from Baker Hughes. For those not familiar, Waygate's no small fry—this outfit's got a century-plus history in non-destructive testing (NDT) services....

Silicone Fluids Market Forecast Hits $10.15B by 2031

Unpacking the Prevailing Expansion The global silicone fluids market is marching on a path to significant growth, projected to hit a hefty $10.15 billion by 2031. Now, if you think that's just another number, let's break down why this matters and how the market is changing its stripes. The Rising Tide of Silicone Applications Silicone fluids are not just sliding under the...

Ascletis Showcases Bold Moves in Obesity Drug Arena

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...

TikTok-Coda: A New Era for Digital Commerce

Redefining Commerce in the Digital Age Alright, folks, let's chew the fat over something that's flipping the script on digital commerce. Coda, the Southeast Asian powerhouse in digital content monetization, is stirring things up with TikTok Gaming. Since June, it's been cooking up one billion views worth of creative potential from users, tightening the grip on digital...

Brightstar Showcases at World Lottery Summit 2026

Brightstar Aims for the Jackpot at WLS 2026 Don't kid yourself—this isn't your granddad's corner-store lottery ticket. Brightstar Lottery PLC, trading as NYSE: BRSL, is pushing the envelope at the World Lottery Summit 2026 in Sydney, flaunting a roster of high-tech and savvy solutions to meet changing player expectations. It's a collision of tradition and tech, all...

Immunic's November Moves: Conferences and Clinical Trials

Immunic Taps Into November Conferences Every now and then, you catch a company that's not just spinning its wheels but making some potentially big waves in their field. This time, it's Immunic, Inc. (Nasdaq: IMUX), stepping into the spotlight. They're strutting their stuff at several investor conferences this November, starting with Boston and New York, then hopping over...

AppLovin Faces Lawsuit Over AI Revenue Claims

AppLovin’s Alleged Missteps: Investors Speak Up Earlier this year, folks holding AppLovin shares were sold a story of grand ambitions. The company's focus was on the promise of AI—dreams of skyrocketing revenue through innovative tools and self-service platforms. But as those promises struggled to take shape, investors pulled back the curtain, and the legal eagles...